GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (OTCPK:IUGNF) » Definitions » Cash Payments

IUGNF (Imugene) Cash Payments : $-67.82 Mil (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Imugene Cash Payments?

Imugene's Cash Payments for the six months ended in Dec. 2023 was $-34.05 Mil.

Imugene's Cash Payments for the trailing twelve months (TTM) ended in Dec. 2023 was $-67.82 Mil.

Imugene Cash Payments Historical Data

The historical data trend for Imugene's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Cash Payments Chart

Imugene Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cash Payments
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.05 -13.84 -26.28 -29.59 -67.55

Imugene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Payments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.37 -14.23 -15.43 -34.05 -33.77

Imugene Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-67.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene Cash Payments Related Terms

Thank you for viewing the detailed overview of Imugene's Cash Payments provided by GuruFocus.com. Please click on the following links to see related term pages.

Imugene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (OTCPK:IUGNF) » Definitions » Cash Payments
Comparable Companies
ASX:RAC ASX:ALA ASX:DXB ASX:LTP ASX:OCC ASX:IMM ASX:EZZ ASX:PAR ASX:RCE ASX:NUZ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
ILA:Germany IMU:Australia
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Website
https://www.imugene.com
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.